TYROSINE KINASE INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER


Cite item

Full Text

Abstract

Considering the findings regarding the excellent frequency response (approximately 70%), survival without disease progression (median approximately of 9 months), better safety profile and the superior quality of life for patients compared with standard chemotherapy, EGFR TKIs in EGFR mutation positive non-small cell lung cancer patients can be now considered as first-line treatment in these patients. Evaluation of epidermal growth factor receptor mutations is necessary for all non-small cell lung cancer patients as the effective prognostic marker of the response to tyrosine kinase inhibitors of EGFR.

About the authors

Svetlana Yu. Sletina

Multifield Medical Center «Vitamed»

Email: sletsvet5@rambler.ru
MD, PhD, Oncologist Moscow, 121309, Russian Federation

E. V Poddubskaya

N.N. Blokhin National Medical Research Center of Oncology; I.M. Seshenov First Moscow State Medical University

Moscow, 115478, Russian Federation; Moscow, 119435, Russian Federation

References

  1. Kosaka T., Yatabe Y., Endoh H. , Kuwano H., Takahashi T., Mitsudomi T. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer: Biological and Clinical Implications. Cancer Research. 2004; 64: 8919-23.
  2. Li A., Chitale D., Riely G., Pao W., Miller V.A., Zakowski M.F. et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J. Mol. Diagn. 2008; 10(3): 242-8.
  3. El-Telbany А., Ma P. Cancer Genes in LungCancer. Genes Cancer. 2012; 3(7-8): 467-80.
  4. Couraud S., Zaicman G., Milleron B., Morin F., Souquet P.J. Lung cancer in never smokers - A review. Eur. J. Cancer. 2012; 48(9): 1229-311.
  5. Rosell R., Moran T, Queralt C., Porta R., Cardenal F., Camps C. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009; 361: 958-67.
  6. Shigematsu H, Lin L, Takahashi T., Nomura M., Suzuki M., Wistuba II et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005; 97: 339-46.
  7. Wu Y.-L., Zhong W.Z., Li L.Y., Zhang X.T., Zhang L., Zhou C.C. et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from the six medical centers in mainland China. J. Thorac. Oncol. 2007; 2: 430-9.
  8. Fukuoka M., Yano S., Giaccone G, Tamura T., Nakagawa K., Douillard J.Y. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003; 21(12), 2237-46.
  9. Kris M. G., Natale R.B., Herbst R.S., Lynch T.J. Jr, Prager D., Belani C.P. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16), 2149-58
  10. Rosell R, Carcereny E, Gervais R., Vergnenegre A., Massuti B., Felip E. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13: 239-46.
  11. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 2011; 29(21):2866-74.
  12. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353(2):123-32.
  13. Wu Y.-L., Zhou C., Liam C.K., Wu G., Liu X., Zhong Z. et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann. Oncol. 2015; 26(9): 1883-9.
  14. Lee C., Brown C., Gralla R., Hirsh V., Thongprasert S., Tsai C.M. et.al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl. Cancer Inst. 2013; 105(9): 595-605.
  15. Socinski M., Evans T., Gettinger S., Hensing T.A., Sequist L.V., Ireland B. et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): 341S-68S.
  16. Reck М., Popat S., Reinmuth N., De Ruysscher D., Kerr K.M., Peters S.et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014; 25 Suppl 3:iii27-39.
  17. Yang J., Hirsh V., Schuler M., Yamamoto N., O’Byrne K.J., Mok T.S. et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations. J. Clin. Oncol. 2013; 31(27): 3342-50.doi: 10.1200/JCO.2012.46.1764.
  18. Wu Y.L., Zhou C., Hu CP., Feng J., Lu S., Huang Y. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harboring EGFR mutations (LUXlung 6): an open-label, randomized phase 3 trial. Lancet Oncol, 2014, 15(2): 213-22.
  19. Yang J.C., Sequist L.V., Zhou C., Schuler M., Geater S.L., Mok T. et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann. Oncol. 2016; 27: 2103-10.
  20. Schuler M., Yang J.C., Park K., Kim J.H, Bennouna J., Chen Y.M. et al. Afatinib beyond progression in patients with advanced non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann. Oncol. 2015, 27(3): 417-23.
  21. Soria J.C., Felip E., Cobo M., Lu S., Syrigos K., Lee K.H.et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015; 16(8): 897-907. doi: 10.1016/S1470-2045(15)00006-6
  22. Park K., Tan E.H., O’Byrne K., Zhang L., Boyer M., Mok T. et al. Afatinib versus gefitinib as first-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7. LBA2, oral presentation at the ESMO Asia 2015 Congress in Singapore, 18-21 December 2015.
  23. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15; 19(8): 2240-7. doi: 10.1158/1078-0432.CCR-12-2246
  24. Mok T.S., Wu Y.-L., Ahn M.-J., Garassino M.C., Kim H.R., Ramalingam S.S.et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N. Engl. J. Med. 2017; 376(7): 629-40. doi: 10.1056/NEJMoa1612674
  25. Mok T.S., Ahn M.-J., Han J., et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J. Clin. Oncol. 2017; 35 (suppl; abstr 900).
  26. Ramalingam S., Reungwetwattana T., Chewaskulyong B., et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Presented at: 2017 ESMO Congress; Madrid, Spain; September 9-12, 2017. Abstract LBA2_PR.
  27. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6): 1710-7.
  28. NSCLC Meta-analyses Collaborative Group, Arriagada R., Auperin A., Burdett S., Higgins J.P., Johnson D.H. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722): 1267-77. doi: 10.1016/S0140-6736(10)60059-1.
  29. Kelly K., Altorki N.K., Eberhardt W.E., O’Brien M.E., Spigel D.R., Crinò L. et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. 2015; 33(34): 4007-14. doi: 10.1200/JCO.2015.61.8918.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies